Facts & Figures
Research focus
Bayer Schering Pharma is active in the clinical development for new products as well as product-accompanying development of already marketed products through all ist business areas and indication areas. In its internal research for active substances, Bayer Schering Pharma concentrates on four core areas: Oncology, Cardiology, Women´s Healthcare, and Diagnostic Imaging. In addition, our clinical development drives the introduction of new products as well as the further development of marketed products across all business areas. In the long term, Bayer Schering Pharma strives for innovation leadership in the areas of cardiology, gynecological therapy and molecular imaging and wants to play a significant role in oncology.
At a glance
| Research expenses 2007 | 1.5 billion EUR |
| In percent of division sales 2007 | 17% |
| Employees in Research & Development | 5,912 (as of Dec 31, 2007) |
| Main research sites | Berlin und Wuppertal, Germany and Berkeley, USA |
| Research focus |
|
Research locations
Research programs and activities will be consolidated into three major research and development sites: Berlin and Wuppertal in Germany, and Berkeley in USA.
The Berlin research group will take leadership for Diagnostic Imaging, Oncology and Women’s Healthcare. Wuppertal will take leadership for the company’s Cardiology, Hematology and Oncology research. Both locations have the technologies for target discovery, lead generation and optimization, drug metabolism and pharmacokinetics, as well as toxicology and clinical pharmacology.
Berkeley will remain an important global research and development center for protein-based biologics drug discovery and will continue to be the home of the modern Kogenate biological manufacturing facility, an innovative medication for the treatment of hemophilia.
